<DOC>
	<DOCNO>NCT02013206</DOCNO>
	<brief_summary>This study evaluate efficacy safety Tarceva two group patient non-small cell lung cancer pre-treated chemotherapy . One group , consist patient never smoke , receive Tarceva 150 mg/day , group , consist current/former smoker , receive Tarceva 150 mg/day increase maximum 300 mg/day . The anticipated time study treatment 1-2 year .</brief_summary>
	<brief_title>A Study Tarceva ( Erlotinib ) Patients With Advanced Non-Small Cell Lung Cancer Naive Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; histologically document advanced nonsmall cell lung cancer ( stage IIIB/IV ) ; Eastern Cooperative Oncology Group ( ECOG ) performance status 02 ; previous chemotherapy . previous therapy act Epidermal Growth Factor Receptor ( EGFR ) axis ; clinical evidence brain metastasis ; unstable systemic disease ; unable take oral medication ; significant ophthalmological abnormality .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>